Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ
Market Cap
$1.17B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
33 of 809
Rank in Industry
28 of 445
Largest Insider Buys in Sector
DAWN Stock Price History Chart
DAWN Stock Performance
About Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Insider Activity of Day One Biopharmaceuticals, Inc.
Over the last 12 months, insiders at Day One Biopharmaceuticals, Inc. have bought $14.98M and sold $4.95M worth of Day One Biopharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Day One Biopharmaceuticals, Inc. have bought $26.19M and sold $23.32M worth of stock each year.
Highest buying activity among insiders over the last 12 months: AI Day1 LLC (10 percent owner) — $14.98M.
The last purchase of 111,387 shares for transaction amount of $1.11M was made by AI Day1 LLC (10 percent owner) on 2023‑10‑20.
List of Insider Buy and Sell Transactions, Day One Biopharmaceuticals, Inc.
| 2024-06-21 | Sale | Ramasastry Saira | director | 10,000 0.012% | $13.19 | $131,877 | -1.57% | |
| 2024-06-10 | Sale | Blackman Samuel C. | HEAD OF R&D | 30,000 0.0347% | $12.62 | $378,588 | +4.56% | |
| 2024-05-16 | Sale | Blackman Samuel C. | HEAD OF R&D | 2,267 0.0026% | $16.08 | $36,450 | -16.79% | |
| 2024-05-16 | Sale | Bender Jeremy | CHIEF EXECUTIVE OFFICER | 7,873 0.009% | $16.08 | $126,588 | -16.79% | |
| 2024-05-16 | Sale | York Charles N II | COO, CFO AND SECRETARY | 2,675 0.0031% | $16.08 | $43,011 | -16.79% | |
| 2024-05-16 | Sale | Dubow Adam | GENERAL COUNSEL | 3,253 0.0037% | $16.08 | $52,304 | -16.79% | |
| 2024-05-10 | Sale | Blackman Samuel C. | HEAD OF R&D | 10,000 0.0117% | $16.37 | $163,743 | -15.84% | |
| 2024-05-03 | Sale | Bender Jeremy | CHIEF EXECUTIVE OFFICER | 9,154 0.0109% | $17.85 | $163,417 | -20.73% | |
| 2024-05-03 | Sale | York Charles N II | COO, CFO AND SECRETARY | 8,078 0.0096% | $17.85 | $144,214 | -20.73% | |
| 2024-05-02 | Sale | Bender Jeremy | CHIEF EXECUTIVE OFFICER | 6 <0.0001% | $17.94 | $108 | -22.34% | |
| 2024-05-02 | Sale | York Charles N II | COO, CFO AND SECRETARY | 200 0.0002% | $17.90 | $3,579 | -22.34% | |
| 2024-05-01 | Sale | Bender Jeremy | CHIEF EXECUTIVE OFFICER | 70,051 0.081% | $17.88 | $1.25M | -22.62% | |
| 2024-05-01 | Sale | York Charles N II | COO, CFO AND SECRETARY | 52,183 0.0604% | $17.89 | $933,397 | -22.62% | |
| 2024-04-18 | Sale | Blackman Samuel C. | HEAD OF R&D | 10,000 0.0116% | $16.02 | $160,163 | -9.49% | |
| 2024-03-25 | Sale | Blackman Samuel C. | HEAD OF R&D | 10,000 0.0122% | $16.01 | $160,055 | -2.73% | |
| 2024-03-11 | Sale | Blackman Samuel C. | HEAD OF R&D | 30,000 0.0345% | $15.24 | $457,314 | -3.50% | |
| 2024-02-27 | Sale | Blackman Samuel C. | HEAD OF R&D | 20,000 0.0212% | $16.11 | $322,166 | -14.47% | |
| 2024-02-16 | Sale | Blackman Samuel C. | HEAD OF RESEARCH AND DEVELOPME | 2,258 0.0026% | $15.25 | $34,430 | -2.90% | |
| 2024-02-16 | Sale | Bender Jeremy | CHIEF EXECUTIVE OFFICER | 7,615 0.0087% | $15.25 | $116,114 | -2.90% | |
| 2024-02-16 | Sale | York Charles N II | COO, CFO AND SECRETARY | 2,666 0.003% | $15.25 | $40,651 | -2.90% |
Insider Historical Profitability
5.29%
| AI Day1 LLC | 10 percent owner | 12929322 14.854% | $13.44 | 8 | 0 | +13.88% |
| Blackman Samuel C. | Head of Research and Developme | 1141081 1.4226% | $13.44 | 0 | 27 | |
| Bender Jeremy | Chief Executive Officer | 654728 0.815% | $13.44 | 0 | 22 | |
| York Charles N II | COO, CFO and Secretary | 224868 0.3104% | $13.44 | 0 | 22 | |
| Ramasastry Saira | director | 40485 0.0463% | $13.44 | 0 | 1 | |
| Dubow Adam | General Counsel | 21731 0.0131% | $13.44 | 0 | 3 | |
| Blavatnik Len | 10684638 12.2751% | $13.44 | 1 | 0 | +23.65% | |
| Canaan XI L.P. | 10 percent owner | 8464301 9.7243% | $13.44 | 1 | 7 | <0.0001% |
| TAKEDA PHARMACEUTICAL CO LTD | 10 percent owner | 6120124 7.0312% | $13.44 | 0 | 4 | |
| Gladstone Michael | 766667 0.8808% | $13.44 | 1 | 0 | +23.65% | |
| Atlas Venture Associates Opportunity I, LLC | 766667 0.8808% | $13.44 | 1 | 0 | +23.65% | |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 741396 0.8518% | $13.44 | 2 | 0 | <0.0001% |
| Grant Julie Papanek | director | 330000 0.3791% | $13.44 | 1 | 24 | <0.0001% |
| Josey John A. | director | 72292 0.0831% | $13.44 | 1 | 0 | <0.0001% |
| Becker Daniel J. | director | 5000 0.0057% | $13.44 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| RA Capital Management, L.P. | $129.02M | 8.94 | 7.81M | 0% | +$0 | 0.13 | |
| Atlas Venture Life Science Advisors Llc | $106.23M | 7.36 | 6.43M | -15.48% | -$19.46M | 10.14 | |
| BlackRock | $83.12M | 5.76 | 5.03M | -1.85% | -$1.56M | <0.01 | |
| The Vanguard Group | $78.87M | 5.46 | 4.77M | +0.1% | +$78,255.24 | <0.01 | |
| Fidelity Investments | $72.76M | 5.04 | 4.4M | +10.99% | +$7.21M | 0.01 | |
| Franklin Templeton Investments | $62.89M | 4.36 | 3.81M | -10.15% | -$7.1M | 0.02 | |
| State Street | $47.82M | 3.31 | 2.89M | -14.36% | -$8.02M | <0.01 | |
| Viking Global Investors | $42.27M | 2.93 | 2.56M | 0% | +$0 | 0.02 | |
| T. Rowe Price | $37.99M | 2.63 | 2.3M | -0.73% | -$280,846.64 | 0.01 | |
| Braidwell Lp | $35.91M | 2.49 | 2.17M | -48.44% | -$33.73M | 2.02 | |
| Goldman Sachs | $35.31M | 2.45 | 2.14M | +0.88% | +$307,965.84 | 0.01 | |
| Janus Henderson | $33.57M | 2.33 | 2.03M | +19.83% | +$5.56M | 0.02 | |
| Deerfield Management | $29.16M | 2.02 | 1.77M | +0.23% | +$68,293.68 | 0.56 | |
| TimesSquare Capital Management LLC | $27.01M | 1.87 | 1.64M | -1.86% | -$510,806.05 | 0.39 | |
| Geode Capital Management | $22.75M | 1.58 | 1.38M | +2.09% | +$464,972.27 | <0.01 | |
| Maverick Capital Ltd | $20.76M | 1.44 | 1.26M | New | +$20.76M | 0.41 | |
| Boxer Capital, LLC | $19.66M | 1.36 | 1.19M | 0% | +$0 | 0.98 | |
| Polar Capital | $19.58M | 1.36 | 1.19M | -14.44% | -$3.3M | 0.11 | |
| Dimensional Fund Advisors | $16.22M | 1.12 | 981,572 | +26.18% | +$3.36M | <0.01 | |
| Driehaus Capital Management LLC | $11.88M | 0.82 | 719,011 | +48.79% | +$3.89M | 0.12 | |
| Parkman Healthcare Partners Llc | $11.43M | 0.79 | 691,812 | +10.56% | +$1.09M | 1.41 | |
| DAFNA Capital Management, LLC | $11.01M | 0.76 | 666,463 | -2.91% | -$330,400.01 | 2.56 | |
| Northern Trust | $9.22M | 0.64 | 558,145 | -3.23% | -$307,387.63 | <0.01 | |
| Sphera Fund | $8.14M | 0.56 | 492,627 | -3.97% | -$336,561.96 | 1.35 | |
| Charles Schwab | $7.56M | 0.52 | 457,652 | +1.04% | +$77,941.36 | <0.01 | |
| Nicholas Investment Partners, L.P. | $5.98M | 0.41 | 361,767 | +19.27% | +$965,577.51 | 0.67 | |
| PFM Health Sciences | $5.87M | 0.41 | 355,251 | -72.75% | -$15.67M | 0.16 | |
| Candriam S C A | $4.79M | 0.33 | 290,014 | 0% | +$0 | 0.03 | |
| Woodline Partners LP | $4.5M | 0.31 | 272,538 | 0% | +$0 | 0.04 | |
| Wellington Management Company | $4.5M | 0.31 | 272,117 | +30.22% | +$1.04M | <0.01 | |
| Schonfeld Group | $3.93M | 0.27 | 237,748 | +32.87% | +$971,607.04 | 0.03 | |
| Morgan Stanley | $3.84M | 0.27 | 232,550 | -30.47% | -$1.68M | <0.0001 | |
| D. E. Shaw & Co. | $3.7M | 0.26 | 224,219 | +14.7% | +$474,619.61 | 0.01 | |
| BNY Mellon | $3.56M | 0.25 | 215,383 | -8.03% | -$310,823.87 | <0.01 | |
| Samsara Biocapital Llc | $3.24M | 0.23 | 196,425 | 0% | +$0 | 0.51 | |
| Rafferty Asset Management Llc | $3.19M | 0.22 | 193,224 | -18.25% | -$712,391.85 | 0.01 | |
| Deutsche Bank | $2.94M | 0.2 | 178,174 | +0.57% | +$16,817.36 | <0.01 | |
| Nuveen | $2.9M | 0.2 | 175,775 | 0% | +$0 | <0.01 | |
| Simplify Asset Management Inc | $2.89M | 0.2 | 175,018 | 0% | +$0 | 0.28 | |
| Citigroup | $2.83M | 0.2 | 171,050 | +71.18% | +$1.17M | <0.01 | |
| Prudential Financial | $2.8M | 0.19 | 169,522 | New | +$2.8M | <0.01 | |
| Laurion Capital Management LP | $2.73M | 0.19 | 164,983 | 0% | +$0 | 0.08 | |
| UBS | $2.71M | 0.19 | 164,018 | +29.52% | +$617,484.48 | <0.01 | |
| Adage Capital Partners Gp L L C | $2.63M | 0.18 | 159,000 | +6% | +$148,680.00 | 0.01 | |
| Marshall Wace | $2.22M | 0.15 | 134,171 | +13.81% | +$268,896.05 | <0.01 | |
| Bank of America | $2.11M | 0.15 | 127,589 | -20.2% | -$533,513.33 | <0.0001 | |
| Macquarie Group | $1.82M | 0.13 | 110,000 | 0% | +$0 | <0.01 | |
| Hudson Bay Capital Management LP | $1.82M | 0.13 | 110,000 | +37.5% | +$495,600.00 | 0.02 | |
| ExodusPoint Capital Management, LP | $1.61M | 0.11 | 97,621 | +138.66% | +$937,156.29 | 0.02 | |
| Swiss National Bank | $1.58M | 0.11 | 95,400 | 0% | +$0 | <0.01 |